Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01950611 | Proteasome Inhibition in Acute Promyelocytic Leukemia(PIAPL) | unknown | Phase 2 | 30 | Christian Medical College, Vellore, IndiaOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT01159301 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2013 |
| clinicaltrials |
| NCT00405743 | A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | completed | Phase 1 / Phase 2 | 153 | Clavis PharmaINDUSTRY | 6 | Sep 18, 2013 | clinicaltrials |
| NCT00882102 | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) | completed | Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2013 | clinicaltrials |
| NCT01701375 | A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia | terminated | Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 9, 2013 | clinicaltrials |
| NCT00718757 | Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | completed | Phase 1 | 4 | St. Jude Children's Research HospitalOTHER | 1 | Aug 28, 2013 | clinicaltrials |
| NCT01380587 | Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia(XCL1) | completed | — | 25 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Aug 27, 2013 | clinicaltrials |
| NCT00684918 | Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) | completed | Phase 2 | 18 | Gemin XINDUSTRY | 2 | Aug 26, 2013 | clinicaltrials |
| NCT00360672 | Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome | completed | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00514722 | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies | terminated | N/A | 4 | University of California, San FranciscoOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00511537 | Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders | completed | — | 30 | University of California, San FranciscoOTHER | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00513318 | Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies | terminated | — | 15 | University of California, San FranciscoOTHER | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00795886 | Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 63 | University of UtahOTHER | 1 | Jul 31, 2013 | clinicaltrials |
| NCT01041040 | LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) | completed | Phase 4 | 200 | PETHEMA FoundationOTHER | 1 | Jul 31, 2013 | clinicaltrials |
| NCT00795132 | Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies | completed | Phase 2 | 47 | University of UtahOTHER | 1 | Jul 30, 2013 | clinicaltrials |
| NCT00334074 | Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | completed | Phase 2 | 30 | Baylor Research InstituteOTHER | 1 | Jul 17, 2013 | clinicaltrials |
| NCT00697671 | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | completed | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT01896752 | Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL | completed | — | 43 | Rigshospitalet, DenmarkOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00927498 | A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old | completed | Phase 3 | 280 | Acute Leukemia French AssociationOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT00002970 | 506U78 in Treating Patients With Refractory Hematologic Cancer | completed | Phase 2 | 148 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT01095926 | Pharmacokinetic Study of Doxorubicin in Children With Cancer(Doxo) | completed | Phase 2 | 101 | University Hospital MuensterOTHER | 4 | Jun 28, 2013 | clinicaltrials |
| NCT01886651 | The Influence of Thiopurine Methyltransferase Activity on Toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia | completed | — | 411 | Rigshospitalet, DenmarkOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00150878 | Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission | terminated | Phase 3 | 198 | University Hospital Carl Gustav CarusOTHER | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00195000 | Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS | completed | Phase 2 | 43 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01492569 | Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting | withdrawn | N/A | 0 | Stanford UniversityOTHER | 1 | Jun 12, 2013 | clinicaltrials |
| NCT01608204 | Busulfan Pharmacokinetic Analysis and GST Pharmacogenetic Profile in Adults Undergoing Hematological Stem Cell Transplantation | completed | — | 63 | Rambam Health Care CampusOTHER | 0 | Jun 11, 2013 | clinicaltrials |
| NCT00010192 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00003934 | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | completed | Phase 3 | 420 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00077467 | Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00079404 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00089349 | Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00003190 | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 3 | 640 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00006363 | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | completed | Phase 3 | 720 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00017472 | Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00070551 | GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00093821 | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors | completed | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00101231 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | terminated | Phase 1 | 88 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | terminated | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01463410 | Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler | terminated | — | 264 | Skyline Diagnostics BVINDUSTRY | 4 | May 29, 2013 | clinicaltrials |
| NCT00358644 | Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) | completed | Phase 2 | 55 | Eisai Inc.INDUSTRY | 1 | May 20, 2013 | clinicaltrials |
| NCT01251809 | Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia | terminated | Phase 1 / Phase 2 | 56 | medac GmbHINDUSTRY | 1 | May 20, 2013 | clinicaltrials |
| NCT00357305 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00165178 | Treatment of Acute Lymphoblastic Leukemia in Children | completed | Phase 3 | 498 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 25, 2013 | clinicaltrials |
| NCT01439217 | Endothelial Function, Arterial Stiffness and Components | completed | — | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 17, 2013 | clinicaltrials |
| NCT00658411 | Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation | terminated | N/A | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00038051 | Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2013 | clinicaltrials |
| NCT00278330 | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT01130662 | Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia | completed | Phase 1 | 16 | University of KansasOTHER | 1 | Mar 26, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Sep 25, 2013source: clinicaltrials